Targeted Knockdown of Overexpressed VEGFA or VEGF164 in Müller cells maintains retinal function by triggering different signaling mechanisms

Oxygen-induced retinopathy (OIR) upregulates Müller cell vascular endothelial growth factor A (VEGFA) that causes intravitreal neovascularization similar to severe retinopathy of prematurity (ROP). Safety concerns exist with anti-VEGF treatment for ROP. We evaluated long-term knockdown of Müller cel...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports Jg. 8; H. 1; S. 2003 - 13
Hauptverfasser:	Becker, Silke, Wang, Haibo, Simmons, Aaron B., Suwanmanee, Thipparat, Stoddard, Gregory J., Kafri, Tal, Hartnett, M. Elizabeth
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	London Nature Publishing Group UK 31.01.2018 Nature Publishing Group
Schlagworte:	13/106 13/51 14/19 38/77 38/89 42/41 692/308 692/617 Animals Astrocytes - metabolism Brain-derived neurotrophic factor Brain-Derived Neurotrophic Factor - metabolism Cells, Cultured Electroretinograms Erythropoietin Erythropoietin - metabolism Gene Knockdown Techniques Gene Silencing Glial Cell Line-Derived Neurotrophic Factor - metabolism Humanities and Social Sciences multidisciplinary Nerve growth factor Nerve Growth Factor - metabolism Neuronal-glial interactions Neuroprotection Neurotrophin 3 Neurotrophin 3 - metabolism Rats Rats, Sprague-Dawley Retina Retina - metabolism Retina - pathology Retinopathy Retinopathy of Prematurity - metabolism Rodents Science Science (multidisciplinary) Signal Transduction Structure-function relationships Vascular endothelial growth factor Vascular Endothelial Growth Factor A - genetics Vascular Endothelial Growth Factor A - metabolism Vascularization
ISSN:	2045-2322, 2045-2322
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Oxygen-induced retinopathy (OIR) upregulates Müller cell vascular endothelial growth factor A (VEGFA) that causes intravitreal neovascularization similar to severe retinopathy of prematurity (ROP). Safety concerns exist with anti-VEGF treatment for ROP. We evaluated long-term knockdown of Müller cell-VEGFA with short-hairpin RNAs to VEGFA or VEGF 164 via subretinal lentivirus delivery (L-VEGFAshRNA, L-VEGF164shRNA) on retinal structure and function in a rat OIR model. Lectin-stained retinal flat mounts analyzed for areas of avascular/total retina (AVA) and intravitreal neovascular/total retina (IVNV) showed initial significantly reduced IVNV by L-VEGFAshRNA and L-VEGF164shRNA compared to control, luciferase-shRNA lentivirus, without late recurrence. Spectral-domain optical coherence tomography (OCT) and immunohistochemical sections (IHC) demonstrated changes in retinal layer thicknesses in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Ganzfeld electroretinograms were increased in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Erythropoietin (EPO), brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, neurotrophin-3 (NT-3) mRNAs were increased in L-VEGFAshRNA, but not L-VEGF164shRNA retinas. In cultured rat Müller cells, knockdown of VEGF upregulated NT-3 and EPO, whereas treatment with EPO activated neuroprotective signaling. Methods to reduce IVNV by selective knockdown of VEGFA, and particularly VEGF 164 , in Müller cells may have fewer deleterious effects than nonselective VEGFA inhibition to all cells in the retina.
AbstractList	Oxygen-induced retinopathy (OIR) upregulates Müller cell vascular endothelial growth factor A (VEGFA) that causes intravitreal neovascularization similar to severe retinopathy of prematurity (ROP). Safety concerns exist with anti-VEGF treatment for ROP. We evaluated long-term knockdown of Müller cell-VEGFA with short-hairpin RNAs to VEGFA or VEGF164 via subretinal lentivirus delivery (L-VEGFAshRNA, L-VEGF164shRNA) on retinal structure and function in a rat OIR model. Lectin-stained retinal flat mounts analyzed for areas of avascular/total retina (AVA) and intravitreal neovascular/total retina (IVNV) showed initial significantly reduced IVNV by L-VEGFAshRNA and L-VEGF164shRNA compared to control, luciferase-shRNA lentivirus, without late recurrence. Spectral-domain optical coherence tomography (OCT) and immunohistochemical sections (IHC) demonstrated changes in retinal layer thicknesses in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Ganzfeld electroretinograms were increased in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Erythropoietin (EPO), brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, neurotrophin-3 (NT-3) mRNAs were increased in L-VEGFAshRNA, but not L-VEGF164shRNA retinas. In cultured rat Müller cells, knockdown of VEGF upregulated NT-3 and EPO, whereas treatment with EPO activated neuroprotective signaling. Methods to reduce IVNV by selective knockdown of VEGFA, and particularly VEGF164, in Müller cells may have fewer deleterious effects than nonselective VEGFA inhibition to all cells in the retina. Oxygen-induced retinopathy (OIR) upregulates Müller cell vascular endothelial growth factor A (VEGFA) that causes intravitreal neovascularization similar to severe retinopathy of prematurity (ROP). Safety concerns exist with anti-VEGF treatment for ROP. We evaluated long-term knockdown of Müller cell-VEGFA with short-hairpin RNAs to VEGFA or VEGF 164 via subretinal lentivirus delivery (L-VEGFAshRNA, L-VEGF164shRNA) on retinal structure and function in a rat OIR model. Lectin-stained retinal flat mounts analyzed for areas of avascular/total retina (AVA) and intravitreal neovascular/total retina (IVNV) showed initial significantly reduced IVNV by L-VEGFAshRNA and L-VEGF164shRNA compared to control, luciferase-shRNA lentivirus, without late recurrence. Spectral-domain optical coherence tomography (OCT) and immunohistochemical sections (IHC) demonstrated changes in retinal layer thicknesses in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Ganzfeld electroretinograms were increased in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Erythropoietin (EPO), brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, neurotrophin-3 (NT-3) mRNAs were increased in L-VEGFAshRNA, but not L-VEGF164shRNA retinas. In cultured rat Müller cells, knockdown of VEGF upregulated NT-3 and EPO, whereas treatment with EPO activated neuroprotective signaling. Methods to reduce IVNV by selective knockdown of VEGFA, and particularly VEGF 164 , in Müller cells may have fewer deleterious effects than nonselective VEGFA inhibition to all cells in the retina. Oxygen-induced retinopathy (OIR) upregulates Müller cell vascular endothelial growth factor A (VEGFA) that causes intravitreal neovascularization similar to severe retinopathy of prematurity (ROP). Safety concerns exist with anti-VEGF treatment for ROP. We evaluated long-term knockdown of Müller cell-VEGFA with short-hairpin RNAs to VEGFA or VEGF via subretinal lentivirus delivery (L-VEGFAshRNA, L-VEGF164shRNA) on retinal structure and function in a rat OIR model. Lectin-stained retinal flat mounts analyzed for areas of avascular/total retina (AVA) and intravitreal neovascular/total retina (IVNV) showed initial significantly reduced IVNV by L-VEGFAshRNA and L-VEGF164shRNA compared to control, luciferase-shRNA lentivirus, without late recurrence. Spectral-domain optical coherence tomography (OCT) and immunohistochemical sections (IHC) demonstrated changes in retinal layer thicknesses in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Ganzfeld electroretinograms were increased in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Erythropoietin (EPO), brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, neurotrophin-3 (NT-3) mRNAs were increased in L-VEGFAshRNA, but not L-VEGF164shRNA retinas. In cultured rat Müller cells, knockdown of VEGF upregulated NT-3 and EPO, whereas treatment with EPO activated neuroprotective signaling. Methods to reduce IVNV by selective knockdown of VEGFA, and particularly VEGF , in Müller cells may have fewer deleterious effects than nonselective VEGFA inhibition to all cells in the retina. Oxygen-induced retinopathy (OIR) upregulates Müller cell vascular endothelial growth factor A (VEGFA) that causes intravitreal neovascularization similar to severe retinopathy of prematurity (ROP). Safety concerns exist with anti-VEGF treatment for ROP. We evaluated long-term knockdown of Müller cell-VEGFA with short-hairpin RNAs to VEGFA or VEGF164 via subretinal lentivirus delivery (L-VEGFAshRNA, L-VEGF164shRNA) on retinal structure and function in a rat OIR model. Lectin-stained retinal flat mounts analyzed for areas of avascular/total retina (AVA) and intravitreal neovascular/total retina (IVNV) showed initial significantly reduced IVNV by L-VEGFAshRNA and L-VEGF164shRNA compared to control, luciferase-shRNA lentivirus, without late recurrence. Spectral-domain optical coherence tomography (OCT) and immunohistochemical sections (IHC) demonstrated changes in retinal layer thicknesses in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Ganzfeld electroretinograms were increased in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Erythropoietin (EPO), brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, neurotrophin-3 (NT-3) mRNAs were increased in L-VEGFAshRNA, but not L-VEGF164shRNA retinas. In cultured rat Müller cells, knockdown of VEGF upregulated NT-3 and EPO, whereas treatment with EPO activated neuroprotective signaling. Methods to reduce IVNV by selective knockdown of VEGFA, and particularly VEGF164, in Müller cells may have fewer deleterious effects than nonselective VEGFA inhibition to all cells in the retina. Oxygen-induced retinopathy (OIR) upregulates Müller cell vascular endothelial growth factor A (VEGFA) that causes intravitreal neovascularization similar to severe retinopathy of prematurity (ROP). Safety concerns exist with anti-VEGF treatment for ROP. We evaluated long-term knockdown of Müller cell-VEGFA with short-hairpin RNAs to VEGFA or VEGF164 via subretinal lentivirus delivery (L-VEGFAshRNA, L-VEGF164shRNA) on retinal structure and function in a rat OIR model. Lectin-stained retinal flat mounts analyzed for areas of avascular/total retina (AVA) and intravitreal neovascular/total retina (IVNV) showed initial significantly reduced IVNV by L-VEGFAshRNA and L-VEGF164shRNA compared to control, luciferase-shRNA lentivirus, without late recurrence. Spectral-domain optical coherence tomography (OCT) and immunohistochemical sections (IHC) demonstrated changes in retinal layer thicknesses in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Ganzfeld electroretinograms were increased in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Erythropoietin (EPO), brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, neurotrophin-3 (NT-3) mRNAs were increased in L-VEGFAshRNA, but not L-VEGF164shRNA retinas. In cultured rat Müller cells, knockdown of VEGF upregulated NT-3 and EPO, whereas treatment with EPO activated neuroprotective signaling. Methods to reduce IVNV by selective knockdown of VEGFA, and particularly VEGF164, in Müller cells may have fewer deleterious effects than nonselective VEGFA inhibition to all cells in the retina.Oxygen-induced retinopathy (OIR) upregulates Müller cell vascular endothelial growth factor A (VEGFA) that causes intravitreal neovascularization similar to severe retinopathy of prematurity (ROP). Safety concerns exist with anti-VEGF treatment for ROP. We evaluated long-term knockdown of Müller cell-VEGFA with short-hairpin RNAs to VEGFA or VEGF164 via subretinal lentivirus delivery (L-VEGFAshRNA, L-VEGF164shRNA) on retinal structure and function in a rat OIR model. Lectin-stained retinal flat mounts analyzed for areas of avascular/total retina (AVA) and intravitreal neovascular/total retina (IVNV) showed initial significantly reduced IVNV by L-VEGFAshRNA and L-VEGF164shRNA compared to control, luciferase-shRNA lentivirus, without late recurrence. Spectral-domain optical coherence tomography (OCT) and immunohistochemical sections (IHC) demonstrated changes in retinal layer thicknesses in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Ganzfeld electroretinograms were increased in L-VEGFAshRNA or L-VEGF164shRNA compared to control. Erythropoietin (EPO), brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, neurotrophin-3 (NT-3) mRNAs were increased in L-VEGFAshRNA, but not L-VEGF164shRNA retinas. In cultured rat Müller cells, knockdown of VEGF upregulated NT-3 and EPO, whereas treatment with EPO activated neuroprotective signaling. Methods to reduce IVNV by selective knockdown of VEGFA, and particularly VEGF164, in Müller cells may have fewer deleterious effects than nonselective VEGFA inhibition to all cells in the retina.
ArticleNumber	2003
Author	Hartnett, M. Elizabeth Becker, Silke Suwanmanee, Thipparat Wang, Haibo Stoddard, Gregory J. Simmons, Aaron B. Kafri, Tal
Author_xml	– sequence: 1 givenname: Silke surname: Becker fullname: Becker, Silke organization: John A. Moran Eye Center, University of Utah – sequence: 2 givenname: Haibo surname: Wang fullname: Wang, Haibo organization: John A. Moran Eye Center, University of Utah – sequence: 3 givenname: Aaron B. surname: Simmons fullname: Simmons, Aaron B. organization: John A. Moran Eye Center, University of Utah – sequence: 4 givenname: Thipparat surname: Suwanmanee fullname: Suwanmanee, Thipparat organization: Gene Therapy Center, University of North Carolina at Chapel Hill – sequence: 5 givenname: Gregory J. surname: Stoddard fullname: Stoddard, Gregory J. organization: Department of Internal Medicine, University of Utah – sequence: 6 givenname: Tal surname: Kafri fullname: Kafri, Tal organization: Gene Therapy Center, University of North Carolina at Chapel Hill – sequence: 7 givenname: M. Elizabeth surname: Hartnett fullname: Hartnett, M. Elizabeth email: ME.Hartnett@hsc.utah.edu organization: John A. Moran Eye Center, University of Utah
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/29386650$$D View this record in MEDLINE/PubMed
BookMark	eNp9Ustu1TAQjVArWkp_gAWyxIZNqF-J7Q1SVbUFUdRNYWslzjh1SeyLnRT6EfwRO34M595SXSqBJdsjzzlHczzzrNjxwUNRvCD4DcFMHiVOKiVLTGRJMRWy5E-KfYp5VVJG6c5WvFccpnSD86qo4kQ9LfaoYrKuK7xf_LhqYg8TdOiDD-ZLF755FCy6vIUI31cRUsqpz6fnZ8coxHVAao6cRx9__RwGiMjAMCQ0Ns5PeScUYXK-GZCdvZlc8Ki9Q1N0fQ_R-R51ztos7SeUXJ9xy9sI5rrxLo3pebFrmyHB4f19UHw6O706eVdeXJ6_Pzm-KA0XfCqhZlLaqrKcM1ErJYTtamwpQMVNi9vsUxkmmGgFN4QyEKolnW2ze0x5S9hB8Xaju5rbETqT64nNoFfRjU2806Fx-u-Md9e6D7e6EopyWWeB1_cCMXydIU16dGn5isZDmJMmSjEmeT4y9NUj6E2YY7a-RlEllVCL4Mvtih5K-dOpDKAbgIkhpQj2AUKwXiZCbyZC54nQ64nQPJPkI5JxU7O0Jbtyw_-pbENNq6VxELfK_jfrNzwizEE
CitedBy_id	crossref_primary_10_3390_pharmaceutics14081605 crossref_primary_10_1016_j_ajo_2020_05_025 crossref_primary_10_1080_17469899_2019_1596026 crossref_primary_10_1096_fba_2025_00146 crossref_primary_10_1007_s13577_025_01233_8 crossref_primary_10_3928_23258160_20231020_01 crossref_primary_10_3390_life11111119 crossref_primary_10_1016_j_drudis_2019_01_023 crossref_primary_10_1016_j_exer_2022_109364 crossref_primary_10_1016_j_ophtha_2018_07_030 crossref_primary_10_1016_j_jare_2025_09_031 crossref_primary_10_1001_jamaophthalmol_2021_5867 crossref_primary_10_1007_s11033_021_06882_0 crossref_primary_10_3389_fped_2021_796143 crossref_primary_10_1007_s40123_023_00744_7 crossref_primary_10_3390_ijms23137354 crossref_primary_10_1146_annurev_vision_093022_021420 crossref_primary_10_3389_fnins_2021_652215 crossref_primary_10_1155_2023_7893104 crossref_primary_10_1080_17469899_2023_2200934 crossref_primary_10_1097_IAE_0000000000003957 crossref_primary_10_1016_j_survophthal_2022_11_007 crossref_primary_10_7554_eLife_80550 crossref_primary_10_1007_s10456_021_09770_0 crossref_primary_10_3389_fcell_2020_00488 crossref_primary_10_1001_jamaophthalmol_2022_2887 crossref_primary_10_3390_ijms22010369 crossref_primary_10_1007_s00417_019_04274_6 crossref_primary_10_22608_APO_201853 crossref_primary_10_3390_brainsci10060330 crossref_primary_10_1007_s10456_018_9618_5 crossref_primary_10_3389_fped_2024_1382858 crossref_primary_10_1001_jamaophthalmol_2022_0030 crossref_primary_10_1016_j_preteyeres_2025_101392 crossref_primary_10_1007_s10456_020_09740_y crossref_primary_10_3390_pharmaceutics13020219 crossref_primary_10_1167_iovs_18_25525 crossref_primary_10_1016_j_yexcr_2021_112470 crossref_primary_10_1038_s41565_024_01851_7 crossref_primary_10_3390_biom15020309
Cites_doi	10.1084/jem.20022027 10.1038/sj.jp.7210842 10.1001/jamaophthalmol.2017.2069 10.1016/j.ajpath.2011.12.033 10.1056/NEJMoa042760 10.1016/j.ajpath.2014.02.016 10.1136/archdischild-2016-310532 10.1001/jamaophthalmol.2017.2195 10.1167/iovs.13-11625 10.1167/iovs.13-13429 10.3928/23258160-20170301-10 10.1001/archophthalmol.2012.592 10.1007/s12035-015-9438-1 10.3109/02713689609017637 10.1038/eye.2016.94 10.1056/NEJMoa1007374 10.1002/path.2611 10.1097/IAE.0000000000001209 10.2353/ajpath.2007.061237 10.1371/journal.pone.0003554 10.1016/j.ajpath.2013.05.011 10.1016/j.ajpath.2011.11.031 10.4161/org.4.4.7415 10.1016/j.preteyeres.2008.05.001 10.1016/j.survophthal.2016.12.004 10.1167/iovs.13-13755 10.1186/1742-4690-8-51 10.1001/jamaophthalmol.2017.1055 10.1016/0014-4835(90)90063-Z 10.3928/23258160-20170630-06 10.1523/JNEUROSCI.15-07-04738.1995
ContentType	Journal Article
Copyright	The Author(s) 2018 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml	– notice: The Author(s) 2018 – notice: 2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM
DOI	10.1038/s41598-018-20278-4
DatabaseName	SpringerOpen Free (Free internet resource, activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles)
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database MEDLINE CrossRef MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Biology
EISSN	2045-2322
EndPage	13
ExternalDocumentID	PMC5792486 29386650 10_1038_s41598_018_20278_4
Genre	Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NIDDK NIH HHS grantid: R01 DK058702 – fundername: NHLBI NIH HHS grantid: R01 HL128119 – fundername: NEI NIH HHS grantid: P30 EY014800 – fundername: NCI NIH HHS grantid: P30 CA016086 – fundername: NEI NIH HHS grantid: T32 EY024234 – fundername: NEI NIH HHS grantid: R01 EY015130
GroupedDBID	0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS EJD ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IPNFZ KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RIG RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFFHD AFPKN CITATION PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c474t-e6388f55f443769977fd60f2ee54cb0b5299c3737b74c123e79b1dfb941024b13
IEDL.DBID	M7P
ISICitedReferencesCount	39
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000423663100082&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2045-2322
IngestDate	Tue Nov 04 02:00:42 EST 2025 Thu Sep 04 16:01:15 EDT 2025 Tue Oct 07 07:45:42 EDT 2025 Mon Jul 21 05:58:33 EDT 2025 Sat Nov 29 04:07:26 EST 2025 Tue Nov 18 22:11:37 EST 2025 Fri Feb 21 02:38:47 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
License	Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c474t-e6388f55f443769977fd60f2ee54cb0b5299c3737b74c123e79b1dfb941024b13
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
OpenAccessLink	https://www.proquest.com/docview/1992989796?pq-origsite=%requestingapplication%
PMID	29386650
PQID	1992989796
PQPubID	2041939
PageCount	13
ParticipantIDs	pubmedcentral_primary_oai_pubmedcentral_nih_gov_5792486 proquest_miscellaneous_1993384933 proquest_journals_1992989796 pubmed_primary_29386650 crossref_primary_10_1038_s41598_018_20278_4 crossref_citationtrail_10_1038_s41598_018_20278_4 springer_journals_10_1038_s41598_018_20278_4
PublicationCentury	2000
PublicationDate	2018-01-31
PublicationDateYYYYMMDD	2018-01-31
PublicationDate_xml	– month: 01 year: 2018 text: 2018-01-31 day: 31
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Scientific reports
PublicationTitleAbbrev	Sci Rep
PublicationTitleAlternate	Sci Rep
PublicationYear	2018
Publisher	Nature Publishing Group UK Nature Publishing Group
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group
References	Hajrasouliha, Garcia-Gonzales, Shapiro, Yoon, Blair (CR9) 2017; 48 Wu (CR7) 2017; 37 Wang (CR13) 2013; 183 Roberto, Tolman, Penn (CR35) 1996; 15 Hu (CR30) 2011; 3 Stone (CR6) 1995; 15 Park, Kim, Park (CR18) 2014; 184 Mintz-Hittner, Kennedy, Chuang (CR4) 2011; 364 McColm, Geisen, Hartnett (CR15) 2004; 10 Haigh (CR8) 2008; 4 Wallace (CR10) 2017; 135 Wang (CR12) 2014; 55 Hartnett (CR22) 2017; 135 Ludwig, Chen, Hernandez-Boussard, Moshfeghi, Moshfeghi (CR2) 2017; 48 Hicks, Courtois (CR33) 1990; 51 Hu (CR24) 2012; 130 Nishijima (CR21) 2007; 171 Jia (CR31) 2016; 53 Shirley Ding (CR20) 2016; 30 Wang (CR19) 2012; 180 Solebo, Teoh, Rahi (CR1) 2017; 102 Jiang (CR14) 2014; 55 Saint-Geniez (CR17) 2008; 3 McCloskey (CR11) 2013; 54 CR26 Mowat (CR27) 2012; 180 Cockrell, van Praag, Santistevan, Ma, Kafri (CR32) 2011; 8 Ishida (CR16) 2003; 198 Bai (CR25) 2009; 219 Robertson (CR34) 2003; 23 Gragoudas (CR29) 2004; 351 Hartnett (CR3) 2017; 62 Molnar, Andreasson, Larsson, Akerblom, Holmstrom (CR23) 2017; 135 Penn (CR5) 2008; 27 von Bartheld (CR28) 1998; 13 JS Penn (20278_CR5) 2008; 27 SL Shirley Ding (20278_CR20) 2016; 30 K Nishijima (20278_CR21) 2007; 171 J Stone (20278_CR6) 1995; 15 CS von Bartheld (20278_CR28) 1998; 13 H Wang (20278_CR19) 2012; 180 JR McColm (20278_CR15) 2004; 10 KA Roberto (20278_CR35) 1996; 15 Y Bai (20278_CR25) 2009; 219 ME Hartnett (20278_CR22) 2017; 135 AEC Molnar (20278_CR23) 2017; 135 ME Hartnett (20278_CR3) 2017; 62 JJ Haigh (20278_CR8) 2008; 4 FM Mowat (20278_CR27) 2012; 180 J Hu (20278_CR24) 2012; 130 20278_CR26 WC Wu (20278_CR7) 2017; 37 Z Jia (20278_CR31) 2016; 53 Y Jiang (20278_CR14) 2014; 55 M Saint-Geniez (20278_CR17) 2008; 3 S Ishida (20278_CR16) 2003; 198 HY Park (20278_CR18) 2014; 184 AF Robertson (20278_CR34) 2003; 23 AL Solebo (20278_CR1) 2017; 102 DK Wallace (20278_CR10) 2017; 135 H Wang (20278_CR13) 2013; 183 AR Hajrasouliha (20278_CR9) 2017; 48 HA Mintz-Hittner (20278_CR4) 2011; 364 D Hicks (20278_CR33) 1990; 51 ES Gragoudas (20278_CR29) 2004; 351 AS Cockrell (20278_CR32) 2011; 8 CA Ludwig (20278_CR2) 2017; 48 H Wang (20278_CR12) 2014; 55 LM Hu (20278_CR30) 2011; 3 M McCloskey (20278_CR11) 2013; 54
References_xml	– volume: 198 start-page: 483 year: 2003 end-page: 489 ident: CR16 article-title: VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization publication-title: J Exp Med doi: 10.1084/jem.20022027 – volume: 23 start-page: 48 year: 2003 end-page: 55 ident: CR34 article-title: Reflections on errors in neonatology: I. The “Hands-Off” years, 1920 to 1950 publication-title: J Perinatol doi: 10.1038/sj.jp.7210842 – volume: 10 start-page: 512 year: 2004 end-page: 520 ident: CR15 article-title: VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP publication-title: Mol Vis – volume: 15 start-page: 4738 year: 1995 end-page: 4747 ident: CR6 article-title: Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia publication-title: Journal of Neuroscience – volume: 135 start-page: 854 year: 2017 end-page: 861 ident: CR23 article-title: Reduction of Rod and Cone Function in 6.5-Year-Old Children Born Extremely Preterm publication-title: JAMA ophthalmology doi: 10.1001/jamaophthalmol.2017.2069 – volume: 180 start-page: 1726 year: 2012 end-page: 1739 ident: CR27 article-title: Endogenous erythropoietin protects neuroretinal function in ischemic retinopathy publication-title: The American journal of pathology doi: 10.1016/j.ajpath.2011.12.033 – volume: 48 start-page: 553 year: 2017 end-page: 562 ident: CR2 article-title: The Epidemiology of Retinopathy of Prematurity in the United States publication-title: Ophthalmic surgery, lasers & imaging retina – volume: 351 start-page: 2805 year: 2004 end-page: 2816 ident: CR29 article-title: Pegaptanib for neovascular age-related macular degeneration publication-title: The New England Journal of Medicine doi: 10.1056/NEJMoa042760 – volume: 184 start-page: 1752 year: 2014 end-page: 1762 ident: CR18 article-title: Neuronal cell death in the inner retina and the influence of vascular endothelial growth factor inhibition in a diabetic rat model publication-title: The American journal of pathology doi: 10.1016/j.ajpath.2014.02.016 – volume: 102 start-page: 853 year: 2017 end-page: 857 ident: CR1 article-title: Epidemiology of blindness in children publication-title: Arch Dis Child doi: 10.1136/archdischild-2016-310532 – volume: 135 start-page: 862 year: 2017 end-page: 863 ident: CR22 article-title: Electroretinographic Responses in the Smallest Eyes publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2017.2195 – volume: 54 start-page: 2020 year: 2013 end-page: 2026 ident: CR11 article-title: Anti-VEGF antibody leads to later atypical intravitreous neovascularization and activation of angiogenic pathways in a rat model of retinopathy of prematurity publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.13-11625 – volume: 55 start-page: 737 year: 2014 end-page: 744 ident: CR12 article-title: Quantitative analyses of retinal vascular area and density after different methods to reduce VEGF in a rat model of retinopathy of prematurity publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.13-13429 – volume: 48 start-page: 255 year: 2017 end-page: 259 ident: CR9 article-title: Reactivation of Retinopathy of Prematurity Three Years After Treatment With Bevacizumab publication-title: Ophthalmic Surg Lasers Imaging Retina doi: 10.3928/23258160-20170301-10 – volume: 130 start-page: 1000 year: 2012 end-page: 1006 ident: CR24 article-title: Reactivation of retinopathy of prematurity after bevacizumab injection publication-title: Arch Ophthalmol doi: 10.1001/archophthalmol.2012.592 – volume: 53 start-page: 5664 year: 2016 end-page: 5670 ident: CR31 article-title: Erythropoietin Attenuates the Memory Deficits in Aging Rats by Rescuing the Oxidative Stress and Inflammation and Promoting BDNF Releasing publication-title: Molecular neurobiology doi: 10.1007/s12035-015-9438-1 – volume: 15 start-page: 932 year: 1996 end-page: 937 ident: CR35 article-title: Long-term retinal vascular abnormalities in an animal model of retinopathy of prematurity publication-title: Curr Eye Res doi: 10.3109/02713689609017637 – volume: 30 start-page: 1293 year: 2016 end-page: 1309 ident: CR20 article-title: Revisiting the role of erythropoietin for treatment of ocular disorders publication-title: Eye (London, England) doi: 10.1038/eye.2016.94 – volume: 364 start-page: 603 year: 2011 end-page: 615 ident: CR4 article-title: Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity publication-title: N Engl J Med doi: 10.1056/NEJMoa1007374 – volume: 219 start-page: 446 year: 2009 end-page: 454 ident: CR25 article-title: M ++ ller cell-derived VEGF is a significant contributor to retinal neovascularization publication-title: The Journal of Pathology doi: 10.1002/path.2611 – volume: 37 start-page: 694 year: 2017 end-page: 701 ident: CR7 article-title: Serum Vascular Endothelial Growth Factor after Bevacizumab or Ranibizumab Treatment for Retinopathy of Prematurity publication-title: Retina doi: 10.1097/IAE.0000000000001209 – volume: 171 start-page: 53 year: 2007 end-page: 67 ident: CR21 article-title: Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury publication-title: The American journal of pathology doi: 10.2353/ajpath.2007.061237 – volume: 3 start-page: e3554 year: 2008 ident: CR17 article-title: Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors publication-title: PLoS One doi: 10.1371/journal.pone.0003554 – volume: 183 start-page: 964 year: 2013 end-page: 974 ident: CR13 article-title: Short hairpin RNA-mediated knockdown of VEGFA in Muller cells reduces intravitreal neovascularization in a rat model of retinopathy of prematurity publication-title: The American journal of pathology doi: 10.1016/j.ajpath.2013.05.011 – volume: 180 start-page: 1243 year: 2012 end-page: 1253 ident: CR19 article-title: VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression publication-title: The American journal of pathology doi: 10.1016/j.ajpath.2011.11.031 – volume: 4 start-page: 247 year: 2008 end-page: 256 ident: CR8 article-title: Role of VEGF in organogenesis publication-title: Organogenesis doi: 10.4161/org.4.4.7415 – volume: 27 start-page: 331 year: 2008 end-page: 371 ident: CR5 article-title: Vascular endothelial growth factor in eye disease publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2008.05.001 – volume: 62 start-page: 257 year: 2017 end-page: 276 ident: CR3 article-title: Advances in understanding and management of retinopathy of prematurity publication-title: Surv Ophthalmol doi: 10.1016/j.survophthal.2016.12.004 – volume: 55 start-page: 824 year: 2014 end-page: 831 ident: CR14 article-title: Targeting Muller cell-derived VEGF164 to reduce intravitreal neovascularization in the rat model of retinopathy of prematurity publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.13-13755 – volume: 13 start-page: 437 year: 1998 end-page: 459 ident: CR28 article-title: Neurotrophins in the developing and regenerating visual system publication-title: Histology and histopathology – ident: CR26 – volume: 8 year: 2011 ident: CR32 article-title: The HIV-1 Rev/RRE system is required for HIV-1 5’ UTR cis elements to augment encapsidation of heterologous RNA into HIV-1 viral particles publication-title: Retrovirology doi: 10.1186/1742-4690-8-51 – volume: 135 start-page: 654 year: 2017 end-page: 656 ident: CR10 article-title: Assessment of Lower Doses of Intravitreous Bevacizumab for Retinopathy of Prematurity: A Phase 1 Dosing Study publication-title: JAMA ophthalmology doi: 10.1001/jamaophthalmol.2017.1055 – volume: 3 start-page: 1541 year: 2011 end-page: 1555 ident: CR30 article-title: EPO reduces reactive gliosis and stimulates neurotrophin expression in Muller cells publication-title: Front Biosci (Elite Ed) – volume: 51 start-page: 119 year: 1990 end-page: 129 ident: CR33 article-title: The growth and behaviour of rat retinal Muller cells . 1. An improved method for isolation and culture publication-title: Exp Eye Res doi: 10.1016/0014-4835(90)90063-Z – volume: 62 start-page: 257 year: 2017 ident: 20278_CR3 publication-title: Surv Ophthalmol doi: 10.1016/j.survophthal.2016.12.004 – volume: 3 start-page: e3554 year: 2008 ident: 20278_CR17 publication-title: PLoS One doi: 10.1371/journal.pone.0003554 – volume: 55 start-page: 824 year: 2014 ident: 20278_CR14 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.13-13755 – volume: 135 start-page: 862 year: 2017 ident: 20278_CR22 publication-title: JAMA Ophthalmol doi: 10.1001/jamaophthalmol.2017.2195 – volume: 37 start-page: 694 year: 2017 ident: 20278_CR7 publication-title: Retina doi: 10.1097/IAE.0000000000001209 – volume: 48 start-page: 255 year: 2017 ident: 20278_CR9 publication-title: Ophthalmic Surg Lasers Imaging Retina doi: 10.3928/23258160-20170301-10 – volume: 27 start-page: 331 year: 2008 ident: 20278_CR5 publication-title: Prog Retin Eye Res doi: 10.1016/j.preteyeres.2008.05.001 – volume: 10 start-page: 512 year: 2004 ident: 20278_CR15 publication-title: Mol Vis – volume: 3 start-page: 1541 year: 2011 ident: 20278_CR30 publication-title: Front Biosci (Elite Ed) – volume: 53 start-page: 5664 year: 2016 ident: 20278_CR31 publication-title: Molecular neurobiology doi: 10.1007/s12035-015-9438-1 – volume: 8 year: 2011 ident: 20278_CR32 publication-title: Retrovirology doi: 10.1186/1742-4690-8-51 – volume: 54 start-page: 2020 year: 2013 ident: 20278_CR11 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.13-11625 – volume: 51 start-page: 119 year: 1990 ident: 20278_CR33 publication-title: Exp Eye Res doi: 10.1016/0014-4835(90)90063-Z – volume: 219 start-page: 446 year: 2009 ident: 20278_CR25 publication-title: The Journal of Pathology doi: 10.1002/path.2611 – volume: 30 start-page: 1293 year: 2016 ident: 20278_CR20 publication-title: Eye (London, England) doi: 10.1038/eye.2016.94 – volume: 180 start-page: 1243 year: 2012 ident: 20278_CR19 publication-title: The American journal of pathology doi: 10.1016/j.ajpath.2011.11.031 – volume: 130 start-page: 1000 year: 2012 ident: 20278_CR24 publication-title: Arch Ophthalmol doi: 10.1001/archophthalmol.2012.592 – volume: 171 start-page: 53 year: 2007 ident: 20278_CR21 publication-title: The American journal of pathology doi: 10.2353/ajpath.2007.061237 – volume: 23 start-page: 48 year: 2003 ident: 20278_CR34 publication-title: J Perinatol doi: 10.1038/sj.jp.7210842 – volume: 180 start-page: 1726 year: 2012 ident: 20278_CR27 publication-title: The American journal of pathology doi: 10.1016/j.ajpath.2011.12.033 – volume: 13 start-page: 437 year: 1998 ident: 20278_CR28 publication-title: Histology and histopathology – volume: 184 start-page: 1752 year: 2014 ident: 20278_CR18 publication-title: The American journal of pathology doi: 10.1016/j.ajpath.2014.02.016 – volume: 198 start-page: 483 year: 2003 ident: 20278_CR16 publication-title: J Exp Med doi: 10.1084/jem.20022027 – volume: 4 start-page: 247 year: 2008 ident: 20278_CR8 publication-title: Organogenesis doi: 10.4161/org.4.4.7415 – volume: 135 start-page: 654 year: 2017 ident: 20278_CR10 publication-title: JAMA ophthalmology doi: 10.1001/jamaophthalmol.2017.1055 – volume: 351 start-page: 2805 year: 2004 ident: 20278_CR29 publication-title: The New England Journal of Medicine doi: 10.1056/NEJMoa042760 – volume: 102 start-page: 853 year: 2017 ident: 20278_CR1 publication-title: Arch Dis Child doi: 10.1136/archdischild-2016-310532 – volume: 364 start-page: 603 year: 2011 ident: 20278_CR4 publication-title: N Engl J Med doi: 10.1056/NEJMoa1007374 – volume: 15 start-page: 932 year: 1996 ident: 20278_CR35 publication-title: Curr Eye Res doi: 10.3109/02713689609017637 – volume: 135 start-page: 854 year: 2017 ident: 20278_CR23 publication-title: JAMA ophthalmology doi: 10.1001/jamaophthalmol.2017.2069 – ident: 20278_CR26 – volume: 183 start-page: 964 year: 2013 ident: 20278_CR13 publication-title: The American journal of pathology doi: 10.1016/j.ajpath.2013.05.011 – volume: 48 start-page: 553 year: 2017 ident: 20278_CR2 publication-title: Ophthalmic surgery, lasers & imaging retina doi: 10.3928/23258160-20170630-06 – volume: 15 start-page: 4738 year: 1995 ident: 20278_CR6 publication-title: Journal of Neuroscience doi: 10.1523/JNEUROSCI.15-07-04738.1995 – volume: 55 start-page: 737 year: 2014 ident: 20278_CR12 publication-title: Invest Ophthalmol Vis Sci doi: 10.1167/iovs.13-13429
SSID	ssj0000529419
Score	2.4234498
Snippet	Oxygen-induced retinopathy (OIR) upregulates Müller cell vascular endothelial growth factor A (VEGFA) that causes intravitreal neovascularization similar to...
SourceID	pubmedcentral proquest pubmed crossref springer
SourceType	Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	2003
SubjectTerms	13/106 13/51 14/19 38/77 38/89 42/41 692/308 692/617 Animals Astrocytes - metabolism Brain-derived neurotrophic factor Brain-Derived Neurotrophic Factor - metabolism Cells, Cultured Electroretinograms Erythropoietin Erythropoietin - metabolism Gene Knockdown Techniques Gene Silencing Glial Cell Line-Derived Neurotrophic Factor - metabolism Humanities and Social Sciences multidisciplinary Nerve growth factor Nerve Growth Factor - metabolism Neuronal-glial interactions Neuroprotection Neurotrophin 3 Neurotrophin 3 - metabolism Rats Rats, Sprague-Dawley Retina Retina - metabolism Retina - pathology Retinopathy Retinopathy of Prematurity - metabolism Rodents Science Science (multidisciplinary) Signal Transduction Structure-function relationships Vascular endothelial growth factor Vascular Endothelial Growth Factor A - genetics Vascular Endothelial Growth Factor A - metabolism Vascularization
Title	Targeted Knockdown of Overexpressed VEGFA or VEGF164 in Müller cells maintains retinal function by triggering different signaling mechanisms
URI	https://link.springer.com/article/10.1038/s41598-018-20278-4 https://www.ncbi.nlm.nih.gov/pubmed/29386650 https://www.proquest.com/docview/1992989796 https://www.proquest.com/docview/1993384933 https://pubmed.ncbi.nlm.nih.gov/PMC5792486
Volume	8
WOSCitedRecordID	wos000423663100082&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M~E dateStart: 20110101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M7P dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: 7X7 dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: BENPR dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: PIMPY dateStart: 20110101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database customDbUrl: eissn: 2045-2322 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000529419 issn: 2045-2322 databaseCode: M2P dateStart: 20110101 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR3LjtMwcMTugsSF9yOwVEbiBtEmjVPHJ7SgFhBqidCCyimqYxsi0WRpsoj9CP6IGz_GjPOAsmIvXKxKduo4M-N5zwA8UjIJ4kAHvhU297mKtC8nNvYF9alB9qFzaV2zCbFYJMulTDuDW92FVfZ3oruodZWTjfyAwiRlIoWcPD3-4lPXKPKudi00dmCPqiRELnQvHWws5MXioexyZYIoOaiRX1FOWUjoMUYFim_zozNC5tlYyb8cpo4Pza7-7wmuwZVOAmWHLcpchwumvAGX2p6Upzfh-5GLDTeavS7xrtSopbPKsjeI8uabi5rFqffTF7NDVm3cD1SFWFGy-c8flFbIyBVQs_WqKMnqUDNKk6QNiYMSFjB1yhp8rY-uCCLrO7Q0jEJJVpQdz9aG8pGLel3fgnez6dHzl37Xs8HPueCNb5CeExvHlnO8uiRKl1ZPAjs2Jua5ChRCROaRiIQSPEeuaYRUobYK4YTSggqj27BbVqW5C4wLkSsdSXxuxalOIWpGK6fPavov5UHYQy7Lu4Lm1Ffjc-Yc61GStdDOENqZg3bGPXg8PHPclvM4d_V-D8msI-06-w1GDx4O00iU9HlXpalO3BpU_TkOHtxp8WfYDuUrqjEYeCC2MGtYQAW_t2fK4pMr_B0L1JYT3PdJj4N_vNY_T3Hv_FPch8tjoocgRH68D7vN5sQ8gIv516aoNyPYEUvhxmQEe8-mi_TtyNktcJyP05EjOJxJX83TD78A1oMxCg
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3LbtNAFL0qKahseD8MBQYJVmDVj3HGs0CogoZGaUIWAbUr47HHJRKxS-xS8hH8Cl_Ajh_j3rEdCBXddcHGsjRjj2d87mvmPgCeKBk6gZM6diayxObKT23ZzQJbUJ0aFB9pIjNTbEKMRuH-vhyvwfc2FobcKlueaBh1WiS0R75FbpIylEJ2Xx59tqlqFJ2utiU0algM9OIETbbyRf81_t-nntfbmbzatZuqAnbCBa9sjYgLsyDIOEfikqj_ZGnXyTytA54oRwXIoBNf-EIJniBf10IqN82U5CiLuXJ9fO8FWOcI9rAD6-P-cHyw3NWhczPuyiY6x_HDrRIlJEWxuQRID002vioBT6m1p70z_zqiNZKvd_V_W7NrcKXRsdl2TRTXYU3nN-BSXXVzcRO-TYz3u07ZIEdpkBYnOSsy9haJWn81fsHY9H7nTW-bFXNzg8Yem-Zs-PMHBU4yOuwo2Sye5rSvUjIKBKUBSUcgnDO1YBUuw6FJ88jaGjQVI2eZmOL_2UxTxPW0nJW34N25rMVt6ORFru8C40IkKvUlPhdzysSItl9sLPaU3qUscFukREmTsp0qh3yKjOuAH0Y1uiJEV2TQFXELni2fOaoTlpzZe7NFTtQwrzL6DRsLHi-bke3Q8sa5Lo5NH98POV4suFPjdTkcapCURdGxQKwgedmBUpqvtuTTjya1eSCkx0Mc93mL-T8-65-zuHf2LB7Bxu5kuBft9UeD-3DZI1p0XNQ-NqFTzY_1A7iYfKmm5fxhQ84MPpw3NfwCQLOGPw
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH4qZREX9iVQwEhwotFkccbxAaGKdqAaGOZQUG8hTmyIxCRlMqXMj-APIW78Md5zFhgqeuuBSxTJThw739vstwA8UjL2Ii_3XCNM5nIV5q4cmsgVVKcGxUeeSWOLTYjJJN7fl9M1-N7FwpBbZccTLaPOq4z2yAfkJiljKeRwYFq3iOn26NnBZ5cqSNFJa1dOo4HIWC-P0Hyrn-5u479-HASjnb3nL922woCbccEXrkb0xSaKDOdIaBJ1IZMPPRNoHfFMeSpCZp2FIhRK8Ax5vBZS-blRkqNc5soP8b1n4KygpOXWbXDa7-_QCRr3ZRun44XxoEZZSfFsPkEzQOONr8rCYwrucT_Nvw5rrQwcXf6fV-8KXGo1b7bVkMpVWNPlNTjf1OJcXodve9YnXudsXKKMyKujklWGvUFS11-ttzA2vdt5Mdpi1dzeoAnIipK9_vmDwikZHYHUbJYWJe221IzCQ2lA0hwI_Uwt2QKX4YNN_si6yjQLRi40KWUFYDNNcdhFPatvwNtTWYubsF5Wpb4NjAuRqTyU-FzKKT8jWoSpteNzepdywO9Qk2RtIneqJ_IpsQ4FYZw0SEsQaYlFWsIdeNI_c9CkMTmx90aHoqRlaXXyG0IOPOybkRnR8qalrg5tnzCMOV4cuNVgtx8O9UrKreg5IFZQ3XegROerLWXx0SY8j4QMeIzjbnb4_-Oz_jmLOyfP4gFcQBJIXu1OxnfhYkBk6fmokmzA-mJ-qO_BuezLoqjn9y1dM3h_2qTwC60sjX4
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Targeted+Knockdown+of+Overexpressed+VEGFA+or+VEGF164+in+M%C3%BCller+cells+maintains+retinal+function+by+triggering+different+signaling+mechanisms&rft.jtitle=Scientific+reports&rft.au=Becker%2C+Silke&rft.au=Wang%2C+Haibo&rft.au=Simmons%2C+Aaron+B.&rft.au=Suwanmanee%2C+Thipparat&rft.date=2018-01-31&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2045-2322&rft.volume=8&rft_id=info:doi/10.1038%2Fs41598-018-20278-4&rft_id=info%3Apmid%2F29386650&rft.externalDocID=PMC5792486
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon